ElectroCore, Inc. is a bioelectronic medicine innovator that has successfully transitioned from clinical development to a commercial growth platform with multiple high-margin revenue streams. Its proprietary nVNS technology is disrupting chronic treatment paradigms for neurological and inflammatory disorders, with its primary product, gammaCore, establishing a leading standard of care within the U.S. federal healthcare network. Integration of the NeuroMetrix acquisition, strong growth in direct-to-consumer wellness, and expansion of military applications mark a transformative year. Record revenues, improved gross margins, and a rapidly diversifying product and customer base demonstrate a proven growth model. However, despite these strategic advances, the market is undervaluing the company dramatically, creating a dislocation between operational achievements and share price. ElectroCore stands out as a platform technology company aligned with global healthcare trends favoring non-opioid, patient-centric therapies.